Status In progress
Process STA
ID number 878

Provisional Schedule

Expected publication 30 May 2018

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors Leo Pharma
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Psoriasis Association
  Psoriasis and Psoriatic Arthritis Alliance
Professional groups British Association of Dermatologists
  British Dermatological Nursing Group
  British Society for Rheumatology
  Royal College of Physicians


Comparator companies AbbVie Limited (adalimumab)
  Accord Healthcare (methotrexate)
  Allergan (acitretin)
  Astellas (tacrolimus)
  B&S Colorama Pharmaceuticals (ciclosporin)
  Celgene (apremilast)
  Cubic Pharmaceuticals (ciclosporin)
  Dexcel-Pharma (ciclosporin, tacrolimus)
  Eli Lilly (ixekizumab)
  Genus Pharmaceuticals (acitretin)
  Hameln Pharmaceuticals (methotrexate)
  Hospira UK (infliximab, methotrexate)
  Janssen (ustekinumab)
  Medac (methotrexate)
  Merck Sharp & Dohme (infliximab)
  Mylan UK (ciclosporin, tacrolimus)
  Napp (infliximab)
  Novartis Pharmaceuticals (secukinumab, ciclosporin)
  Orion Pharma UK (methotrexate)
  Pfizer (etanercept, methotrexate)
  Sandoz (methotrexate, tacrolimus)
  Teva UK (methotrexate, tacrolimus)
  Wockhardt UK (methotrexate)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups AbbVie Limited (adalimumab)
  Accord Healthcare (methotrexate) (not participating)
  Allergan (acitretin) (not participating)
  Astellas (tacrolimus) (not participating)
  B&S Colorama Pharmaceuticals (ciclosporin) (not participating)
  Celgene (apremilast)
  Cubic Pharmaceuticals (ciclosporin) (not participating)
  Dexcel-Pharma (ciclosporin, tacrolimus) (not participating)
  Eli Lilly (ixekizumab)
  Genus Pharmaceuticals (acitretin) (not participating)
  Hameln Pharmaceuticals (methotrexate) (not participating)
  Hospira UK (infliximab, methotrexate) (not participating)
  Janssen (ustekinumab)
  Medac (methotrexate) (not participating)
  Merck Sharp & Dohme (infliximab)
  Mylan UK (ciclosporin, tacrolimus) (not participating)
  Napp (infliximab)
  Novartis Pharmaceuticals (secukinumab, ciclosporin)
  Orion Pharma UK (methotrexate) (not participating)
  Pfizer(etanercept, methotrexate) (not participating)
  Sandoz (methotrexate, tacrolimus) (not participating)
  Teva UK (methotrexate, tacrolimus) (not participating)
  Wockhardt UK (methotrexate) (not participating)


Key events during the development of the guidance:

Date Update
04 January 2018 Committee meeting: 1
10 August 2017 In progress, In progress
02 August 2017 Invitation to participate
26 July 2017 Referral
24 January 2017 Draft scope documents

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance